CytomX Therapeutics CTMX Proceeds from maturities of short-term investments
Proceeds from maturities of short-term investments at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's proceeds from maturities of short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's proceeds from maturities of short-term investments?
- CytomX Therapeutics (CTMX) reported proceeds from maturities of short-term investments of $50M in Q1 2026.
- How has CytomX Therapeutics's proceeds from maturities of short-term investments changed year-over-year?
- CytomX Therapeutics's proceeds from maturities of short-term investments decreased by 1.0% year-over-year, from $50.5M to $50M.
- What is the long-term trend for CytomX Therapeutics's proceeds from maturities of short-term investments?
- Over 3 years (2021 to 2025), CytomX Therapeutics's proceeds from maturities of short-term investments has grown at a 2.4% compound annual growth rate (CAGR), from $124M to $133M.